55 related articles for article (PubMed ID: 38519578)
21. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
Baxter NN; Kennedy EB; Bergsland E; Berlin J; George TJ; Gill S; Gold PJ; Hantel A; Jones L; Lieu C; Mahmoud N; Morris AM; Ruiz-Garcia E; You YN; Meyerhardt JA
J Clin Oncol; 2022 Mar; 40(8):892-910. PubMed ID: 34936379
[TBL] [Abstract][Full Text] [Related]
22. Impact of Inadequate Number of Lymph Nodes Examined on Survival in Stage II Colon Cancer.
Wu Q; Zhang Z; Chen Y; Chang J; Jiang Y; Zhu D; Wei Y
Front Oncol; 2021; 11():736678. PubMed ID: 34616683
[TBL] [Abstract][Full Text] [Related]
23. A national evaluation of the use and survival impact of adjuvant chemotherapy in Stage II colon cancer from the national cancer database.
Reif de Paula T; Gorroochurn P; Simon HL; Haas EM; Keller DS
Colorectal Dis; 2022 Jan; 24(1):40-49. PubMed ID: 34605166
[TBL] [Abstract][Full Text] [Related]
24. Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status.
Akce M; Zakka K; Jiang R; Williamson S; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
Front Oncol; 2021; 11():592351. PubMed ID: 33859934
[TBL] [Abstract][Full Text] [Related]
25. The Predictive and Guidance Value of Signet Ring Cell Histology for Stage II/III Colon Cancer Response to Chemotherapy.
Jiang H; Shao D; Zhao P; Wu Y
Front Oncol; 2021; 11():631995. PubMed ID: 33708632
[TBL] [Abstract][Full Text] [Related]
26. Trajectories of perioperative serum carcinoembryonic antigen and colorectal cancer outcome: A retrospective, multicenter longitudinal cohort study.
Li Z; Li C; Pu H; Pang X; Wang Y; Zhang D; Lei M; Cheng X; Zhao Y; Lu G; Ding Y; Cai L; Liu Z; Zhang T; You D
Clin Transl Med; 2021 Feb; 11(2):e293. PubMed ID: 33634994
[No Abstract] [Full Text] [Related]
27. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.
Iveson TJ; Sobrero AF; Yoshino T; Souglakos I; Ou FS; Meyers JP; Shi Q; Grothey A; Saunders MP; Labianca R; Yamanaka T; Boukovinas I; Hollander NH; Galli F; Yamazaki K; Georgoulias V; Kerr R; Oki E; Lonardi S; Harkin A; Rosati G; Paul J
J Clin Oncol; 2021 Feb; 39(6):631-641. PubMed ID: 33439695
[TBL] [Abstract][Full Text] [Related]
28. A Novel Prognostic Model Incorporating Carcinoembryonic Antigen in 3-Week or Longer Postoperative Period for Stage III Colon Cancer: A Multicenter Retrospective Study.
Fan J; Liu Y; Cai X; Wang J; Guo R; Ji Y; Li C; Xu Y; Li X; Zhang C; Zhang R; Zhu J; Cai S
Front Oncol; 2020; 10():566784. PubMed ID: 33335852
[TBL] [Abstract][Full Text] [Related]
29. Stage migration resulting from inadequate number of examined lymph nodes impacts prognosis in stage II colon cancer after radical surgery.
Xie D; Song X; Tong L
Int J Colorectal Dis; 2021 May; 36(5):959-969. PubMed ID: 33174134
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
Yamazaki K; Yamanaka T; Shiozawa M; Manaka D; Kotaka M; Gamoh M; Shiomi A; Makiyama A; Munemoto Y; Rikiyama T; Fukunaga M; Ueki T; Shitara K; Shinkai H; Tanida N; Oki E; Sunami E; Ohtsu A; Maehara Y; Yoshino T
Ann Oncol; 2021 Jan; 32(1):77-84. PubMed ID: 33121997
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis.
Mazaki J; Katsumata K; Kasahara K; Tago T; Wada T; Kuwabara H; Enomoto M; Ishizaki T; Nagakawa Y; Tsuchida A
BMC Cancer; 2020 Sep; 20(1):922. PubMed ID: 32977767
[TBL] [Abstract][Full Text] [Related]
32. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Argilés G; Tabernero J; Labianca R; Hochhauser D; Salazar R; Iveson T; Laurent-Puig P; Quirke P; Yoshino T; Taieb J; Martinelli E; Arnold D;
Ann Oncol; 2020 Oct; 31(10):1291-1305. PubMed ID: 32702383
[No Abstract] [Full Text] [Related]
33. Mucinous Histology Might Be an Indicator for Enhanced Survival Benefit of Chemotherapy in Stage II Colon Cancer.
Huang Y; Ge K; Fu G; Chu J; Wei W
Front Med (Lausanne); 2020; 7():205. PubMed ID: 32582726
[No Abstract] [Full Text] [Related]
34. Clinical Significances of Positive Postoperative Serum CEA and Post-preoperative CEA Increment in Stage II and III Colorectal Cancer: A Multicenter Retrospective Study.
You W; Yan L; Cai Z; Xie L; Sheng N; Wang G; Wu X; Wang Z
Front Oncol; 2020; 10():671. PubMed ID: 32509572
[No Abstract] [Full Text] [Related]
35. Left colon as a novel high-risk factor for postoperative recurrence of stage II colon cancer.
Wang L; Hirano Y; Ishii T; Kondo H; Hara K; Obara N; Yamaguchi S
World J Surg Oncol; 2020 Mar; 18(1):54. PubMed ID: 32160919
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
37. Cancer statistics, 2020.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2020 Jan; 70(1):7-30. PubMed ID: 31912902
[TBL] [Abstract][Full Text] [Related]
38. Overuse and Limited Benefit of Chemotherapy for Stage II Colon Cancer in Young Patients.
Birkett RT; Chamely E; Concors SJ; Bleier JI; Aarons CB; Shanmugan S; Saur NM; Paulson EC
Clin Colorectal Cancer; 2019 Dec; 18(4):292-300. PubMed ID: 31447135
[TBL] [Abstract][Full Text] [Related]
39. Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer:
Auclin E; Taieb J; Lepage C; Aparicio T; Faroux R; Mini E; Folprecht G; Salazar R; Benetkiewicz M; Banzi M; Louvet C; Van Laethem JL; Tabernero J; Hickish T; de Gramont A; André T; Vernerey D
Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1153-1161. PubMed ID: 31263053
[TBL] [Abstract][Full Text] [Related]
40. Deficient mismatch repair as a prognostic marker in stage II colon cancer patients.
Gkekas I; Novotny J; Fabian P; Nemecek R; Palmqvist R; Strigård K; Pecen L; Svoboda T; Gurlich R; Gunnarsson U
Eur J Surg Oncol; 2019 Oct; 45(10):1854-1861. PubMed ID: 31186203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
